| 11.65 0.19 (1.66%) | 05-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 16.14 | 1-year : | 17.89 |
| Resists | First : | 13.82 | Second : | 15.31 |
| Pivot price | 13.23  |
|||
| Supports | First : | 11.4 | Second : | 9.49 |
| MAs | MA(5) : | 11.88 |
MA(20) : | 13.61 |
| MA(100) : | 12.31 |
MA(250) : | 8.38 |
|
| MACD | MACD : | -0.4 |
Signal : | 0 |
| %K %D | K(14,3) : | 7.3 |
D(3) : | 12.8 |
| RSI | RSI(14): 37.7 |
|||
| 52-week | High : | 17.64 | Low : | 2.95 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ OMER ] has closed above bottom band by 19.6%. Bollinger Bands are 44.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 12.01 - 12.07 | 12.07 - 12.13 |
| Low: | 11.33 - 11.39 | 11.39 - 11.45 |
| Close: | 11.55 - 11.65 | 11.65 - 11.75 |
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
Fri, 22 May 2026
[144] OMEROS CORP SEC Filing - Stock Titan
Thu, 14 May 2026
How Omeros’ (OMER) Noncash-Boosted Q1 Profit Swing Will Impact Investors - Sahm
Wed, 13 May 2026
Omeros: Q1 Earnings Snapshot - KTVB
Wed, 13 May 2026
Omeros (NASDAQ: OMER) turns Q1 profit on YARTEMLEA sales and CMS gains - Stock Titan
Wed, 13 May 2026
Earnings Flash (OMER) Omeros Corporation Reports Q1 Revenue $9.9M, Vs. FactSet Est of $4.2M - Moomoo
Wed, 13 May 2026
New transplant drug gains Medicare billing code, logs $11M sales - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 72 (M) |
| Shares Float | 70 (M) |
| Held by Insiders | 3.5 (%) |
| Held by Institutions | 44.3 (%) |
| Shares Short | 15,790 (K) |
| Shares Short P.Month | 17,070 (K) |
| EPS | 1.13 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.7 |
| Profit Margin | 871 % |
| Operating Margin | -176.1 % |
| Return on Assets (ttm) | -25.3 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.27 |
| Sales Per Share | 0.13 |
| EBITDA (p.s.) | -1.45 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -95 (M) |
| Levered Free Cash Flow | 181 (M) |
| PE Ratio | 10.21 |
| PEG Ratio | 0.8 |
| Price to Book value | -6.9 |
| Price to Sales | 85.26 |
| Price to Cash Flow | -8.9 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|